ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC 50 of 40 nM.In VitroML-109 (Compound 2) is a full agonist at TSHR with an EC 50 of 40 nM and, like compound 1, it has no activity at FSHR or LHCGR. ML-109
ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC 50 of 40 nM.In VitroML-109 (Compound 2) is a full agonist at TSHR with an EC 50 of 40 nM and, like compound 1, it has no activity at FSHR or LHCGR. ML-109
ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC 50 of 40 nM.In VitroML-109 (Compound 2) is a full agonist at TSHR with an EC 50 of 40 nM and, like compound 1, it has no activity at FSHR or LHCGR. ML-109
ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC 50 of 40 nM.In VitroML-109 (Compound 2) is a full agonist at TSHR with an EC 50 of 40 nM and, like compound 1, it has no activity at FSHR or LHCGR. ML-109
ML375 (VU0483253) is a potent, highly selective, brain-penetrant and orally active M5 mAChR negative allosteric modulator (NAM) with IC 50 s of 300 nM and 790 nM for human and rat M5, respectively. ML375 is inactive at human and rat M1-M4.In
ML375 (VU0483253) is a potent, highly selective, brain-penetrant and orally active M5 mAChR negative allosteric modulator (NAM) with IC 50 s of 300 nM and 790 nM for human and rat M5, respectively. ML375 is inactive at human and rat M1-M4.In
ML375 (VU0483253) is a potent, highly selective, brain-penetrant and orally active M5 mAChR negative allosteric modulator (NAM) with IC 50 s of 300 nM and 790 nM for human and rat M5, respectively. ML375 is inactive at human and rat M1-M4.In
ML375 (VU0483253) is a potent, highly selective, brain-penetrant and orally active M5 mAChR negative allosteric modulator (NAM) with IC 50 s of 300 nM and 790 nM for human and rat M5, respectively. ML375 is inactive at human and rat M1-M4.In
DBCO-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic , Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VAIn VitroADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. MCE
DBCO-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic , Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VAIn VitroADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. MCE